5,173 reports of this reaction
5.7% of all RANITIDINE HYDROCHLORIDE reports
#3 most reported adverse reaction
BLADDER CANCER is the #3 most commonly reported adverse reaction for RANITIDINE HYDROCHLORIDE, manufactured by WinCo Foods, LLC. There are 5,173 FDA adverse event reports linking RANITIDINE HYDROCHLORIDE to BLADDER CANCER. This represents approximately 5.7% of all 90,318 adverse event reports for this drug.
RANITIDINE HYDROCHLORIDE has an overall safety score of 95 out of 100. Patients taking RANITIDINE HYDROCHLORIDE who experience bladder cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLADDER CANCER is moderately reported among RANITIDINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to bladder cancer, the following adverse reactions have been reported for RANITIDINE HYDROCHLORIDE:
The following drugs have also been linked to bladder cancer in FDA adverse event reports:
BLADDER CANCER has been reported as an adverse event in 5,173 FDA reports for RANITIDINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLADDER CANCER accounts for approximately 5.7% of all adverse event reports for RANITIDINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience bladder cancer while taking RANITIDINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.